Hepatitis C
Show Only Open Trials
1.
Efficacy and Safety Evaluation of a Regimen Consisting of Peginterferon Lambda-1a + Ribavirin + Daclatasvir (Lambda + RBV + DCV) in HCV Genotype 1b Treatment naïve Patients or Prior Relapsers to Peginterferon Alfa + Ribavirin (Alfa + RBV) Therapy
- Study Status: Open to Enrollment
- Sponsor: Bristol-Myers Squibb
- Disease Status and/or Stage: Chronic Hepatitis C, Untreated or Previously Treated
- Protocol ID: BMS AI452021
2.
A5294: A Prospective, Phase III, Open-Label Study of Boceprevir, Pegylated-Interferon Alfa 2b and Ribavirin in HCV/HIV Coinfected Subjects
- Study Status: Open to Enrollment
- Sponsor: NIAID
- Disease Status and/or Stage: HIV/Hepatitis C Co-Infection
3.
A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response in patients treated with DAA-containing regimens for chronic hepatitis C infection
- Study Status: Open to Enrollment
- Sponsor: Roche
- Disease Status and/or Stage: Chronic Hepatitis C
